2. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
Congestive Heart Failure
A global concern
In USA > 5 Million people have heart
failure
35% asymptomatic
50% stable – on oral drug therapy
10 – 15 % advanced heart failure
Heart transplantation best therapy
Only 2500 hearts available in USA each
year
6. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
Cellular cardiomyoplasty:
Concept
Growing interest as a potential new means of
improving prognosis of heart failure
Assumption
LV dysfunction largely DUE to loss of critical number
of cardiomyocytes
Partly reversed by implantation of new contractile
cells into post infarction scars
Cell types
Autologous skeletal myoblasts
Bone marrow stem cells
Autologous origin
Cardiomyocyte / endothelial trans - differentiation potential
7. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
Stem Cells
Totipotent : capacity to turn into any type
of cell in the body, including placenta.
Pluripotent : can turn into any cell other
than the placenta.
Multipotent : can form a limited number of
cells. e.g. HSC
8. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
CELLULAR CARDIO MYOPLASTY
CELL SOURCES & LIMITATIONS
CELLSOURCE ETHICAL
PROBLEMS
ACQUISITION
CONCERNS
REJECTION ONCOGENICITY
FEATAL CARDIO
MYOCYTES
YES YES YES NO
ADULTCARDIO
MYOCYTES
NO YES NO YES
SKELETAL
MYOBLAST
NO YES NO NO
EMBRYONIC
STEM CELL
YES YES YES YES
MARROW
STROMAL CELL
NO NO NO NO
JTCVS NOV 2000
12. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
Myocardium Repair: The best choice
Cardiocytes
Taylor et al. 1998
Skeletal myoblasts
Menasche et al. Lancet,2001
Bone marrow stem cells
Stamm et al.Lancet,2003
Wang et al. Circulation, 2002
Orilic et al. Nature, 2001
Toma et al, Circulation2001
26. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
Cellular Cardiomyoplasty: AIIMS study
Patients with CAD undergoing CABG &
having reduced LV function with an area
of non-viable myocardium
Bone marrow obtained from same patient
& processed to isolate stem cells
Cells injected directly into myocardium at
the end of CABG procedure
29. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
AIIMS study: patients
Basal NYHA class:
mean: 2.9 0.7
range: 2-4
Basal Left ventricular status:
Akinetic areas: all patients
In anterior wall in 86%
Basal LVEF: 33 16%
30. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
AIIMS study: procedure
Bone marrow obtained at the start of
CABG surgery from sternum
Bone marrow sent for stem cell
preparation while CABG performed
Processed stem cells injected in infarcted
areas at the end of CABG procedure,
including non-revascularisable areas
33. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
Separation of Stem Cells/MNCs
Dilution of the Bone marrow
Ficoll density gradient centrifugation
Washing of MNC
Viability of the MNC
Cell count
-Strauer et al. Circulation, 2002
-Galinanes et al. AHA, 2002
41. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
AIIMS study: Stem Cell details
Volume of bone marrow harvested: 348 ml
Cell count: 1522 million per ml
Mononuclear cell percentage: 892%
Viability: 991%
Final volume: 125 ml
CD 34 count: 1.21 0.6
54. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
Stress Thallium 20 segment analysis
No. of scarred segments reduced:
From 5.4 2.7 to 4.6 2.6
No. of normal segments increased:
From 6.2 3.9 to 8.2 4.1
More segments showed improvement:
Improved: mean 5.8 segments
No change: mean 14.2 segments
Worsened: mean 0 segments
66. CELLULAR CARDIOMYOPLASTY
WWW.AIIMS.AC.IN
Conclusions
Bone marrow derived stem cell
transplantation during CABG is feasible
and safe.
Bone marrow obtained from sternum at
the time of CABG provides adequate
number of stem cells
Early data is suggests that this procedure
may be beneficial in patients with scars /
recent infarct in left ventricle.
Further studies are needed